Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE TENOFOVIR ALAFENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE TENOFOVIR ALAFENAMIDE.
EMTRICITABINE vs EMTRICITABINE; TENOFOVIR ALAFENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to emtricitabine triphosphate, which competes with the natural substrate deoxycytidine 5'-triphosphate and inhibits HIV-1 reverse transcriptase by incorporating into viral DNA, causing chain termination. Tenofovir alafenamide is a prodrug of tenofovir, an NRTI; it is converted to tenofovir, then phosphorylated to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase by competing with deoxyadenosine 5'-triphosphate and causing DNA chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet orally once daily containing emtricitabine 200 mg and tenofovir alafenamide 25 mg.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Emtricitabine: 10 hours (prolonged to ~40 hours in severe renal impairment, CrCl <30 mL/min). Tenofovir alafenamide: 0.51 hours (active metabolite tenofovir diphosphate has intracellular half-life of 150-180 hours in PBMCs, supporting once-daily dosing).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Emtricitabine: 86% renal (active tubular secretion and glomerular filtration), 14% fecal. Tenofovir alafenamide: <1% renal, >97% fecal (as unchanged drug or metabolites, primarily via hepatobiliary excretion).
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."